Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma (RIST-rNB-2011)

Written By 3B Digital

Chief Investigator: Selim Corbacioglu

Sponsor: University of Regensburg

This study aims to improve the outcome of patients with relapsed or refractory neuroblastoma.

Further details about the trial can be found at clinicaltrials.gov database: https://clinicaltrials.gov/ct2/show/NCT01467986

3B Digital https://www.3bweb.com
Previous

A Phase I study of 131-1 mIBG followed by Nivolumab and Dinutuximab beta Antibody in children with relapsed/refractory Neuroblastoma. (The MINIVAN trial)
Next

Prospective multicentre clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients (NB2015-LR)